Ferritin nanocage fused with LAG3 binding peptide and use thereof as anticancer immunotherapeutic agent
The ferritin nanocage fused with LAG3 and PD-L1 binding peptides addresses the limitations of current cancer immunotherapy by enhancing immune activity and targeting cancer tissues, offering a next-generation immune checkpoint blocking approach.
Patent Information
- Application Number
- PCT/KR2024/006092
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-03
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-07
AI Technical Summary
Current cancer immunotherapy using immune checkpoint inhibitors like CTLA-4, PD-1, and PD-L1 antibodies is not effective for many patients, as immune cells expressing LAG3 lose their anticancer function, necessitating a drug delivery platform that enhances immune checkpoint inhibitory function and stability, particularly for targeting cancer tissues.
A ferritin nanocage fused with LAG3 binding peptides and optionally PD-L1 binding peptides is developed, allowing specific binding to immune checkpoint receptors, enhancing immune activity and achieving dual-functional immune checkpoint blocking effects, including effective targeting of brain cancer tissues.
The ferritin nanocage technology increases immune activity by specifically binding to LAG3 receptors, blocks immune checkpoints, and demonstrates enhanced anticancer effects by selectively targeting cancer tissues, potentially overcoming limitations of existing immune checkpoint blocking therapies.
Smart Images

Figure KR2024006092_07112024_PF_FP_ABST
Abstract
Description
Ferritin nanocage fused with LAG3 binding peptide and its use as an anticancer immunotherapeutic agent
[0001] The present invention relates to a ferritin nanocage fused with a LAG3 binding peptide and its use as an anticancer immunotherapeutic agent, and to the use of the ferritin nanocage fused with the LAG3 binding peptide for immune checkpoint control and combination anticancer immunotherapy.
[0002] Cage proteins are proteins that can precisely self-assemble from low-molecular-weight monomers to form macromolecules tens to hundreds of times their original molecular weight. In nature, viral capsid proteins, ferritin, heat shock proteins, and Dps proteins are examples of this type. Each monomer constituting the cage interacts with neighboring monomers in a highly regular and precise manner, while the interior of the cage is empty. Due to the container-like properties of cage proteins, which provide isolation between the interior and exterior, they are frequently utilized as drug delivery systems in the medical field.
[0003] In the field of cage protein-based material transport, active research is being conducted on both viral and non-viral vectors. Currently, adenoviruses and other viral transporters are being studied extensively, while ferritin and heat shock proteins are being studied as non-viral transporters. However, existing viral transporters have raised safety concerns due to the genes inherent in the virus itself.
[0004] Ferritin is an intracellular protein that stores and releases iron. Ferritin typically exists in the body as a hollow, spherical cage. This cage is composed of 24 subunits, which are classified into heavy chains and light chains based on their structure.
[0005] Recently, selective monoclonal antibodies targeting immune checkpoint molecules have achieved unprecedented success in the treatment of human cancers. This advancement in cancer immunotherapy represents a new milestone in the history of cancer treatment. Lymphocyte-activation gene 3 (LAG3), one of the immune checkpoint molecules, has become an attractive therapeutic target in various cancers. It is primarily upregulated upon T cell activation and is also abundant in exhausted T cells commonly found in tumor-infiltrating lymphocytes. Panel studies of human and mouse tumor samples have revealed that LAG3 is highly expressed in tumor-infiltrating lymphocytes as well as lymphocytes in secondary immune organs. LAG3 is expressed on various types of lymphocytes and dendritic cells.
[0006] Although a significant number of cancer patients respond to treatment with blockade of key immune checkpoints such as CTLA-4, PD-1, and PD-L1, many patients still do not respond. Furthermore, when immune cells (T cells) that infiltrate cancer tissues and are exposed, they express not only PD-1 but also other immune checkpoint inhibitor proteins, such as LAG3, thereby losing their anticancer effect and rendering immune checkpoint inhibitory therapies that block PD-1 / PD-L1 ineffective. Therefore, there is a pressing need to develop a drug delivery platform that enhances the immune checkpoint inhibitory function and stability of peptides that bind to LAG3, while enabling effective delivery to cancer tissues.
[0007] The present invention provides a fusion polypeptide in which a LAG3 binding peptide is inserted into a human ferritin heavy chain fragment consisting of an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, a fusion polypeptide in which a PD-L1 binding peptide consisting of an amino acid sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 is additionally bound to the N-terminus of the fusion polypeptide, and a ferritin nanocage comprising the fusion polypeptide.
[0008] In addition, the present invention provides a polynucleotide encoding the fusion polypeptide, an expression vector comprising the polynucleotide, and a transformant isolated by transformation with the expression vector.
[0009] In addition, the present invention aims to provide a pharmaceutical composition for preventing or treating cancer, which comprises the ferritin nanocage as an active ingredient.
[0010] In addition, the present invention aims to provide a drug delivery composition comprising the ferritin nanocage as an active ingredient.
[0011] To solve the above problem, the present invention provides a fusion polypeptide having a LAG3 binding peptide inserted into a human ferritin heavy chain fragment consisting of an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, a fusion polypeptide further having a PD-L1 binding peptide consisting of an amino acid sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 bound to the N-terminus of the fusion polypeptide, and a ferritin nanocage comprising the fusion polypeptide.
[0012] Additionally, the present invention provides a polynucleotide encoding the fusion polypeptide.
[0013] In addition, the present invention provides an expression vector comprising the polynucleotide.
[0014] In addition, the present invention provides a transformant isolated by transformation with the expression vector.
[0015] In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the ferritin nanocage as an active ingredient.
[0016] In addition, the present invention aims to provide a drug delivery composition comprising the ferritin nanocage as an active ingredient.
[0017] The present invention relates to a ferritin nanocage fused with a LAG3-binding peptide and its use as an anticancer immunotherapeutic agent. Peptides that bind to the immune checkpoint receptor LAG3 (LAG3pep1: CIRNDPAVC and LAG3pep2: CSVLNASGC) are each fused to loops protruding from the surface of human ferritin to form a cage, thereby producing a nanocage displaying 24 LAG3-binding peptides. The nanocage of the present invention specifically binds to the LAG3 receptor and blocks LAG3, thereby enhancing immune activity, and effectively targets brain cancer tissues by passing through the BBB, thereby exhibiting an anticancer effect. In addition, an immune checkpoint blocking nanocage fused with a LAG3-binding peptide and a PD-L1-binding peptide specifically binds to each receptor, thereby exhibiting a dual-functional immune checkpoint blocking effect. Therefore, the nanocage technology of the present invention is expected to be a next-generation drug that overcomes the limitations of immune checkpoint blocking therapy using antibodies.
[0018] Figure 1 shows the design and purification results of immune checkpoint proteins fused with Lag3 binding peptide 1 (CIRNDPAVC) or 2 (CSVLNASGC).
[0019] Figure 2 shows the results of comparative analysis of the binding affinity of each manufactured fusion protein (cultured cell binding and protein binding analysis using a surface plasmon resonance device).
[0020] Figure 3 shows the results of designing a bifunctional PDL1 / Lag3 blocking ferritin fusion protein by simultaneously displaying PDL1 binding peptide 1 or 2 or Lag3 binding peptide 1 or 2 on ferritin.
[0021] Figure 4 shows the results of observing the cage formation and particle size of each manufactured fusion protein using TEM and DLS.
[0022] Figure 5 shows the results of comparative analysis of binding affinity (cultured cell binding) of each manufactured fusion protein.
[0023] Figure 6 shows the tumor-targeting effect of immune checkpoint blocking nanocages.
[0024] Figure 7 shows the results of the in vivo immuno-cancer effects of P1L1 and P1L2.
[0025] Figure 8 shows the biotoxicity confirmation results of Lag3 binding peptide display ferritin fusion proteins (L1, L2, P1L1, P1L2) through blood and serum analysis.
[0026] The present invention provides a fusion polypeptide in which a LAG3 binding peptide is inserted into a human ferritin heavy chain fragment, comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
[0027] In addition, the present invention provides a fusion polypeptide in which a PD-L1 binding peptide consisting of an amino acid sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 is additionally linked to the N-terminus of the fusion polypeptide.
[0028] Preferably, the fusion polypeptide may be one in which the LAG3 binding peptide is inserted into the loop region of the 4th and 5th helices of the human ferritin heavy chain fragment.
[0029] Preferably, the LAG3 binding peptide may be, but is not limited to, SEQ ID NO: 3 or SEQ ID NO: 4.
[0030] Preferably, the additionally bonded portion of the fusion polypeptide may further include a linker.
[0031] Meanwhile, the fusion polypeptides P1L1, P1L2, P2L1 and P2L2 described in the present invention may each be composed of an amino acid sequence represented by SEQ ID NO: 7 to SEQ ID NO: 10.
[0032]
[0033] In addition, the present invention provides a ferritin nanocage comprising the fusion polypeptide. Specifically, the ferritin nanocage may be in a form in which a LAG3 binding peptide and a PD-L1 binding peptide are fused to the outer surface of ferritin.
[0034] In the present invention, 'ferritin' is a type of intracellular protein that stores and releases iron. Ferritin generally has a hollow spherical cage shape in the body, and the cage is composed of 24 ferritin monomers, and the ferritin monomers are classified into heavy chains and light chains according to their structure. In the present invention, the ferritin protein may be used without limitation as long as each of these proteins has the activity to form a cage-shaped complex protein as a unit.
[0035] In the present invention, a "nanocage" is a protein cage formed by the precise self-assembly property of low-molecular-weight monomers and having a space inside. Viral capsid proteins, ferritin, heat shock proteins, and Dps proteins are examples of these. The nanocage of the present invention is characterized by including the fusion polypeptide of the present invention as a monomer constituting the nanocage. The term "self-assembly" used in the present invention refers to the property of certain molecules to form a specific nanostructure on their own without any special external stimulus or artificial induction.
[0036] The nanocage of the present invention may be a complex protein in which the fusion polypeptide of the present invention is regularly arranged as a unit, and more preferably, it may be formed by regularly arranging 24 fusion polypeptides of the present invention in a three-dimensional manner.
[0037]
[0038] Additionally, the present invention provides a polynucleotide encoding the fusion polypeptide.
[0039] The above “polynucleotide” is a polymer of deoxyribonucleotides or ribonucleotides existing in single-stranded or double-stranded form. It encompasses RNA genome sequences, DNA (gDNA and cDNA), and RNA sequences transcribed therefrom, and includes analogs of natural polynucleotides unless otherwise specified.
[0040] The polynucleotide comprises not only a nucleotide sequence encoding the fusion polypeptide, but also a complementary sequence thereto. The complementary sequence includes not only a perfectly complementary sequence but also a substantially complementary sequence.
[0041] Additionally, the polynucleotide may be modified. Such modifications include additions, deletions, or non-conservative or conservative substitutions of nucleotides. A polynucleotide encoding the amino acid sequence is also interpreted to include a nucleotide sequence that exhibits substantial identity to the nucleotide sequence. Such substantial identity may be a sequence that exhibits at least 80% homology, at least 90% homology, or at least 95% homology when the nucleotide sequence and any other sequence are aligned to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art.
[0042]
[0043] In addition, the present invention provides an expression vector comprising the polynucleotide.
[0044]
[0045] In addition, the present invention provides a transformant isolated by transformation with the expression vector.
[0046] In the present invention, “vector” means a self-replicating DNA molecule used to transport a clone gene (or other piece of clone DNA).
[0047] In the present invention, “vector” means a plasmid, viral vector or other vector known in the art capable of expressing an inserted nucleic acid in a host cell, and may be a polynucleotide encoding the fusion polypeptide of the present invention operably linked to a conventional expression vector known in the art. The expression vector may generally include a replication origin capable of proliferating in a host cell, one or more expression control sequences (e.g., promoter, enhancer, etc.) that control expression, a selective marker, and a polynucleotide encoding the fusion polypeptide of the present invention operably linked to the expression control sequence. The transformant may be one transformed by the expression vector.
[0048] Preferably, the transformant can be obtained by introducing an expression vector containing a polynucleotide encoding the fusion polypeptide of the present invention into a host cell by a method known in the art, for example, but not limited to, transient transfection, microinjection, transduction, cell fusion, calcium phosphate precipitation, liposome-mediated transfection, DEAE dextran-mediated transfection, polybrene-mediated transfection, electroporation, gene gun, and other known methods for introducing nucleic acids into cells (Wu et al., J. Bio. Chem., 267:963-967, 1992; Wu and Wu, J. Bio. Chem., 263:14621-14624, 1988).
[0049]
[0050] In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the ferritin nanocage as an active ingredient.
[0051] Preferably, the cancer may be, but is not limited to, breast cancer, colon cancer, rectal cancer, brain tumor, lung cancer, liver cancer, skin cancer, esophageal cancer, testicular cancer, kidney cancer, stomach cancer, bladder cancer, ovarian cancer, bile duct cancer, gallbladder cancer, uterine cancer, cervical cancer, prostate cancer, head and neck cancer, pancreatic cancer, and squamous cell carcinoma.
[0052] Preferably, the pharmaceutical composition can inhibit immune checkpoints.
[0053]
[0054] The pharmaceutical composition of the present invention can be prepared using pharmaceutically suitable and physiologically acceptable adjuvants in addition to the active ingredient, and the adjuvants may include solubilizers such as excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, glidants, or flavoring agents. The pharmaceutical composition of the present invention can be preferably formulated as a pharmaceutical composition by additionally including one or more pharmaceutically acceptable carriers in addition to the active ingredient for administration. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and may include saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders and lubricants can be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions and emulsions, pills, capsules, granules or tablets.
[0055] The pharmaceutical formulation form of the pharmaceutical composition of the present invention may be granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, and sustained-release formulations of the active compound, etc. The pharmaceutical composition of the present invention may be administered in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalation, topical, rectal, oral, intraocular or intradermal routes. The effective amount of the active ingredient of the pharmaceutical composition of the present invention refers to the amount required for the prevention or treatment of a disease. Therefore, it can be adjusted according to various factors including the type of disease, the severity of the disease, the types and contents of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, body weight, general health condition, sex and diet, administration time, administration route and secretion rate of the composition, treatment period, and concurrently used drugs. Although not limited thereto, for example, in the case of adults, the composition of the present invention may be administered once to several times a day, and in the case of a compound, the composition may be administered at a dose of 0.1 ng / kg to 10 g / kg.
[0056]
[0057] In addition, the present invention provides a drug delivery composition comprising the ferritin nanocage as an active ingredient.
[0058] The ferritin nanocage according to the present invention can be used as an intelligent drug delivery system that selectively delivers drugs to cancer tissue. If the ferritin nanocage of the present invention is loaded with a known drug and used for cancer treatment, the drug's efficacy can be increased because the ferritin nanocage of the present invention selectively delivers the drug only to cancer tissue and cancer cells, while significantly reducing the drug's side effects on normal tissue.
[0059] The above drug is an anticancer agent, and any anticancer agent that can be loaded into the ferritin nanocage of the present invention can be used without limitation as long as it is conventionally used for the treatment of cancer. Examples include doxorubicin, paclitaxel, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, Gleevec (STI-571), cisplatin, 5-fluorouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, and nitrosoureas.
[0060] Below, the present invention is described in detail using examples that do not limit the scope of the invention. The following examples are intended to concretize the invention and do not limit or restrict the scope of the invention. Therefore, anything that a specialist in the technical field can easily infer from the detailed description and examples of the invention is interpreted as falling within the scope of the invention.
[0061]
[0062] <Example 1> Design and purification of immune checkpoint proteins fused with Lag3-binding peptide 1 (CIRNDPAVC) or 2 (CSVLNASGC)
[0063] 1. Experimental method
[0064] (1) Production of Lag3N1, Lag3L1, Lag3C1 (cage with Lag3 peptide1 inserted into the N-terminus, loop of helix 4 and 5, and C-terminus) and Lag3N2, Lag3L2, Lag3C2 (cage with Lag3 peptide2 inserted into the N-terminus, loop of helix 4 and 5, and C-terminus) DNA
[0065] The human ferritin heavy chain fragment (1-161) gene sequence or human ferritin heavy chain (1-183) gene sequence was amplified by PCR from a cDNA library reverse transcribed from human mRNA and inserted into the pET-28a plasmid using a genetic recombination method. The gene sequence of Lag3-binding peptide 1 or 2 was chemically synthesized and inserted into the nitrogen terminus of the human ferritin heavy chain fragment (1-161) using restriction enzymes KpnI and NheI or into the carbon terminus of the human ferritin heavy chain fragment (1-161) using restriction enzymes SpeI and XhoI. When inserting the peptide into the nitrogen terminus of ferritin, a GG sequence peptide was inserted between them to increase the degree of freedom, and when inserting the peptide into the carbon terminus of ferritin, a longer flexible linker (GGGSGGGGSG) was inserted to increase the degree of freedom and prevent the peptide from being hidden inside the ferritin. Additionally, the gene sequence of Lag3 binding peptide 1 or 2 was inserted between the genes corresponding to the 4th and 5th helices of the human ferritin heavy chain (1-183) gene using restriction enzymes BamHI and ApaI.
[0066]
[0067] (2) Purification of Lag3N1, Lag3L1, Lag3C1 and Lag3N2, Lag3L2, Lag3C2 proteins
[0068] E. coli (BL21) transformed with each plasmid was inoculated into LB medium and grown in a shaking incubator at 37°C. OD 600When the value reached 0.5, IPTG was added to the medium to induce protein overexpression. Lysis buffer was added to E. coli and disrupted by sonication. The lysate (supernatant) collected by centrifugation was reacted with Ni-NTA beads at 4℃ for 2 hours, and the lysate that did not bind to the beads was filtered through a chromatography column, and the beads were washed with a wash buffer containing 30 mM imidazole. The endotoxin of E. coli was removed with a wash buffer containing 0.1% Triton X-114, and Triton X-114 was removed with the wash buffer. The proteins were eluted and purified using each elution buffer containing 100 mM and 300 mM imidazole, respectively. For each protein, more than 95% homogeneous purified protein was recovered by SDS PAGE.
[0069]
[0070] 2. Experimental results
[0071] The human ferritin heavy chain fragment has three junctions at the N-terminus, a loop connecting helices 4 and 5, and the C-terminus, which enable peptide display on the surface when 24 monomers polymerize to form a cage. Through the present invention, fusion proteins (Lag3N1, Lag3L1, Lag3C1 and Lag3N2, Lag3L2, Lag3C2) in which Lag3-binding peptide 1 or 2 was inserted into each of these three junctions were designed and manufactured, and the differences in structure, biophysical properties, and binding affinity were elucidated (Fig. 1).
[0072] The 3D structural models of Lag3N1, Lag3L1, and Lag3C1 calculated through computer simulation are as shown in Fig. 1A, and the gene sequence schematic is as shown in Fig. 1B. Fig. 1C shows the results of verifying stable expression and purification in E. coli by confirming protein bands at the same positions as the theoretical monomer sizes of each protein by performing electrophoresis of each protein through SDS-polyacrylamide gel electrophoresis and staining the gel with Coomassie Brilliant Blue.
[0073]
[0074] <Example 2> Comparative analysis of the binding affinity of each manufactured fusion protein (protein binding analysis using cultured cell binding and surface plasmon resonance device)
[0075] 1. Experimental method
[0076] Confocal laser scanning microscopy: HEK293T cells were transfected with GFP-Lag3 and mock-transfected with GFP alone. GFP-Lag3 expression was confirmed by treatment with Lag3 antibodies. To prevent nonspecific binding of proteins, cells were blocked with 1% BSA in DMEM for 30 minutes at room temperature. The BSA was removed, and the fusion proteins Lag3N1, Lag3L1, and Lag3C1, and Lag3N2, Lag3L2, and Lag3C2 (100 nM) were incubated at 4°C for 1 hour. After washing with PBS, the cells were stained with anti-human ferritin heavy chain antibody (1:500 ratio) for 1 hour (green). After fixation with 4% paraformaldehyde, the cells were observed using a confocal microscope. To observe the nucleus, DAPI was dissolved in PBS at a ratio of 1:1000 and stained (blue) for 5-10 minutes at room temperature (Fig. 2A).
[0077] It is known that treatment of Jurkat T cells with phorbol 12-myristate 13-acetate (PMA), ionomycin, and chloroquine induces Lag3 receptor expression. Forty-eight hours after drug treatment, FITC-labeled Lag3N1, Lag3L1, and Lag3C1, as well as Lag3N2, Lag3L2, and Lag3C2 fusion proteins (100 nM) were incubated at 4°C for 1 hour. After washing with PBS, the cells were analyzed for binding by reading the fluorescence of the cells using a flow cytometer. At this time, the labeled fluorescence of each added protein was corrected to have the same value. Binding to cells not treated with IFN-γ was observed as a control (Fig. 2B).
[0078] Lag3-Fc protein was coated on the surface of a gold sensor chip for surface plasmon resonance to which protein A was attached. The Lag3N1, Lag3L1, and Lag3C1 and the Lag3N2, Lag3L2, and Lag3C2 fusion proteins, dissolved in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 2 mM DTT solution, were flowed onto the gold sensor chip conjugated with Lag3-Fc protein, respectively, and the binding kinetics were analyzed. The right channel without Lag3-Fc protein was used as a reference to correct the resonance measurement values (Fig. 2C).
[0079]
[0080] 2. Experimental results
[0081] Lag3N1, Lag3L1, Lag3C1, and Lag3N2, Lag3L2, and Lag3C2 fusion proteins bound to HEK293T cells expressing Lag3. No difference in binding affinity was observed between the fusion proteins. In contrast, when quantitative analysis of binding to Jurkat cells expressing Lag3 was performed using flow cytometry, Lag3L1 and Lag3L2 showed superior binding affinity than the other fusion proteins. When binding affinity to purified Lag3 receptor was measured using a surface plasmon resonance device, it was confirmed that Lag3L1 and Lag3L2 showed superior binding affinity than the other fusion proteins. Based on these results, we concluded that the Lag3-binding peptide would have excellent binding function when inserted into the loops of helices 4 and 5 of ferritin (Fig. 2).
[0082]
[0083] <Example 3> Design of a dual-functional PDL1 / Lag3-blocking ferritin fusion protein by simultaneously displaying PDL1-binding peptide 1 or 2 or Lag3-binding peptide 1 or 2 on ferritin.
[0084] Lag3 is expressed not only on exhausted CD8+ T cells and exhibits immunomodulatory functions, but also on other immune cells such as Treg cells. Therefore, when blocked alone, its anticancer modulatory function was found to be minimal. However, it is known that the anticancer effect is doubled when blocked in combination with the PD-L1 / PD-1 immune checkpoint regulatory function. In fact, many clinical trials are underway that combine Lag3 antibodies with antibodies that block PD-L1 / PD-1. Previous studies have shown that PD-L1 binding peptides, when inserted into the N-terminus of ferritin, exhibit anticancer effects by binding and blocking PD-L1. Based on this, a bifunctional fusion protein was designed in which PD-L1 binding peptide 1 (CLQKTPKQC) or PD-L1 binding peptide 2 (CVRARTR) was inserted into the N-terminus of ferritin and Lag3 binding peptide 1 or 2 was inserted into the loop of the 4th and 5th helices (Fig. 3).
[0085]
[0086] <Example 4> Observation of cage formation and particle size of each manufactured fusion protein using TEM and DLS
[0087] Each protein was purified using Ni-NTA beads from E. coli overexpressing P1L1, P1L2, P2L1, and P2L2-ICBN (immune checkpoint blocking nanocage) fusion proteins, and transmission electron microscopy (TEM) analysis was performed to confirm whether the fusion proteins formed ferritin nanocages. It was confirmed that each protein formed a nanocage, and the size of each cage was confirmed by dynamic light scattering (DLS) analysis (Fig. 4).
[0088]
[0089] <Example 5> Comparative analysis of the binding affinity of each manufactured fusion protein (binding analysis using cultured cells and surface plasmon resonance device)
[0090] 1. Experimental method
[0091] Confocal laser scanning microscopy: HEK293T cells transfected with GFP-Lag3 and cells transfected with GFP only (mock) were treated with Lag3 antibody to confirm the expression of GFP-Lag3 in GFP-Lag3-transfected cells. To prevent nonspecific binding of proteins, cells were blocked with 1% BSA dissolved in DMEM for 30 minutes at room temperature. After removing the BSA, the cells were incubated with Lag3L1, Lag3L2, P1L1, P1L2, P2L1, P2L2-ICBN, or wild type ferritin (100 nM) at 4°C for 1 hour. After washing with PBS, the cells were stained with anti-human ferritin heavy chain antibody (1:500 ratio) for 1 hour (green). The cells were fixed with 4% paraformaldehyde and observed under a confocal microscope. To observe the nucleus, DAPI was dissolved in PBS at a ratio of 1:1000 and stained (blue) for 5-10 minutes at room temperature (Fig. 5A).
[0092] The binding to triple-negative breast cancer cells (MDA-MB 231) expressing PD-L1 was measured. MCF-7 breast cancer cells that do not express PD-L1 were observed as a control. To prevent nonspecific binding of PD-L1 protein, 1% BSA was dissolved in media and blocked at room temperature for 30 minutes. After removing BSA, the cells were incubated with PpNF (P1), Pp2NF (P2), P1L1, P1L2, P2L1, P2L2-ICBN, or wild type ferritin (100 nM) at 4°C for 1 hour. After washing with PBS, the cells were stained (green) with anti-human ferritin heavy chain antibody (1:500 ratio) for 1 hour. The cells were fixed with 4% paraformaldehyde and observed under a confocal microscope. To observe the nucleus, DAPI was dissolved in PBS at a ratio of 1:1000 and stained (blue) for 5-10 minutes at room temperature (Fig. 5B).
[0093] After coating the Lag3 protein on the surface of a gold sensor chip for surface plasmon resonance, the Lag3L1, Lag3L2, P1L1, and P1L2 ICBN fusion proteins dissolved in a solution of 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 2 mM DTT were flowed onto the gold sensor chip bound to the Lag3 protein, and the binding kinetics were analyzed (Fig. 5C).
[0094]
[0095] 2. Experimental results
[0096] P1L1, P1L2, P2L1, and P2L2-ICBN fusion proteins bound to HEK293T cells expressing Lag3 and MDA-MB231 cells expressing PD-L1. They did not bind to HEK293T cells (mock-transfected) that do not express Lag3, indicating specific binding to Lag3. They did not bind to MCF-7 cells that do not express PD-L1, but nonspecific binding was observed with P2, P2L1, and P2L2. The wt ferritin control did not bind to any cells. This suggests that P1L1 and P1L2 may act more specifically to PD-L1 (Fig. 5). When binding to purified Lag3 receptors was measured using a surface plasmon resonance device, it was found that Lag3L1, Lag3L2, P1L1, and P1L2 all bound specifically. Among these, P1L2 had the best binding affinity.
[0097]
[0098] <Example 6> Tumor-targeting effect of immune checkpoint blocking nanocages
[0099] 1. Experimental method
[0100] 1×10 MC38 colon cancer cells in 100 μl of PBS 6 The dogs were injected subcutaneously into the right thigh of 6-week-old BALB / c mice. When the tumor size was approximately 100 mm3, 200 μl each of P1L2 (10 mg / kg) and ferritin wildtype (10 mg / kg) proteins labeled with Flamma-675 and dissolved in saline were injected into the tail vein of each mouse.
[0101] The in vivo distribution of the protein was examined 1, 4, 8, 12, 18, and 24 hours after injection using the IVIS fluorescence imaging system. After 48 hours, the mice were sacrificed, and the tumors, heart, lungs, liver, kidneys, and spleen were removed to determine how much protein remained within the organs.
[0102] Additionally, confocal laser scanning microscopy was performed. Glioblastoma cells (GL26) expressing the PD-L1 receptor were cultured and then reacted with P1, P2, P1L1, P1L2, P2L1, and P2L2 ICBN (100 nM) at 4°C for 1 hour. After washing with PBS, the cells were stained with anti-human ferritin heavy chain antibody (1:200 ratio) for 1 hour (green). After fixation with 4% paraformaldehyde, the cells were observed using a confocal microscope. To observe the nuclei, DAPI was diluted in PBS at a ratio of 1:1000 and stained for 5–10 minutes at room temperature (blue). Wild-type ferritin and PpNF (P1) and Pp2NF (P2), which have been proven to bind to PD-L1, were used as controls.
[0103]
[0104] 2. Experimental results
[0105] It was found that P1L2 had increased tumor targeting ability compared to wild-type ferritin (tumor targeting by EPR effect) (Fig. 6A).
[0106] In addition, we confirmed that the P1L1, P1L2, P2L1, and P2L2 bifunctional fusion proteins bind to PD-L1-expressing glial cells in the same manner as P1 and P2, which display PD-L1 binding peptides (Fig. 6B). Based on this, we inferred that P1L1 and P1L2 could be targeted and developed as glioblastoma therapeutics, just as PpNF crosses the BBB and targets glioblastoma.
[0107]
[0108] <Example 7> In vivo immuno-cancer effects of P1L1 and P1L2
[0109] 1. Experimental method
[0110] MC38 cells were injected subcutaneously into the upper right thigh of BALB / c wild-type mice. When the tumor size was approximately 100 mm3, the mice were randomly divided into four groups. P1, L1, L2, P1L1, P1L2, or wt Ferritin dissolved in saline, bicarbonate buffer (pH 7.4) at a concentration of 10 mg / kg each, and therapeutic anti-PD-L1 antibody and Lag3 antibody were injected into each mouse via the tail vein. The tumor size and body weight of the mice were measured during the five injections, once every other day (anti-PD-L1 antibody was injected three times, once every three days) (Fig. 7B and Fig. 7C).
[0111]
[0112] 2. Experimental results
[0113] The P1L1 and P1L2 fusion proteins significantly inhibited tumor growth compared to the P1 or L1, L2 fusion proteins (Fig. 7B). In particular, P1L2 showed a superior anticancer effect than the group co-administered with PDL1 and Lag3 antibodies. There was no change in body weight in any fusion protein-administered group compared to control mice (Fig. 7C).
[0114] These results showed that P1L2 effectively inhibits tumor growth through its immune checkpoint suppression effect.
[0115]
[0116] <Example 8> Biotoxicity of Lag3-binding peptide display ferritin fusion proteins (L1, L2, P1L1, P1L2) through blood and serum analysis
[0117] After the anti-tumor animal experiment, when the mice were sacrificed, blood and serum were collected from each group, and the amounts of red blood cells, hemoglobin, hematocrit, white blood cells, and neutrophils in the blood and blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate aminotransferase in the serum were measured and compared.
[0118] In the group of mice treated with the Lag3 binding peptide display ferritin fusion protein, no hepatotoxicity or renal toxicity was observed, and there were no significant changes in hematology (Fig. 8).
[0119]
[0120] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A fusion polypeptide comprising a human ferritin heavy chain fragment having an amino acid sequence represented by sequence number 1 or sequence number 2, into which a LAG3 binding peptide is inserted.
2. In the first paragraph, the fusion polypeptide is characterized in that the LAG3 binding peptide is inserted into the loop region of the 4th and 5th helices of the human ferritin heavy chain fragment.
3. A fusion polypeptide according to claim 1, characterized in that the LAG3 binding peptide has SEQ ID NO: 3 or SEQ ID NO:
4.
4. A fusion polypeptide in which a PD-L1 binding peptide consisting of an amino acid sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 is additionally linked to the N-terminus of the fusion polypeptide according to paragraph 1.
5. A ferritin nanocage comprising a fusion polypeptide of any one of claims 1 to 4.
6. In the fifth paragraph, the ferritin nanocage is characterized in that the ferritin nanocage is in a form in which a LAG3 binding peptide and a PD-L1 binding peptide are fused to the outer surface of the ferritin.
7. A polynucleotide encoding a fusion polypeptide of any one of claims 1 to 4.
8. An expression vector comprising the polynucleotide of clause 7.
9. A transformant isolated by transformation with the expression vector of Article 8.
10. A pharmaceutical composition for preventing or treating cancer, comprising the ferritin nanocage of Article 5 as an active ingredient.
11. A pharmaceutical composition for preventing or treating cancer, characterized in that in paragraph 10, the cancer is any one selected from the group consisting of breast cancer, colon cancer, rectal cancer, brain tumor, lung cancer, liver cancer, skin cancer, esophageal cancer, testicular cancer, kidney cancer, stomach cancer, bladder cancer, ovarian cancer, bile duct cancer, gallbladder cancer, uterine cancer, cervical cancer, prostate cancer, head and neck cancer, pancreatic cancer, and squamous cell carcinoma.
12. A pharmaceutical composition for preventing or treating cancer, characterized in that the pharmaceutical composition in claim 10 suppresses an immune checkpoint.
13. A drug delivery composition comprising the ferritin nanocage of clause 5 as an active ingredient.
14. A drug delivery composition according to claim 13, characterized in that the drug is an anticancer agent.
Citation Information
Patent Citations
Protein nanocages with enhanced mucosal penetration for targeted tissue and intracellular delivery
JP2019533645A
TV control system and tv control device for the same
KR102039857B1
Targeted conjugates and particles and formulations thereof
WO2016004043A1
Cell-to-cell delivery of RNA circuits
WO2023023528A1
